Independent Research Analysts Give MorphoSys (ETR:MOR) a €116.00 Price Target

Independent Research set a €116.00 ($134.88) target price on MorphoSys (ETR:MOR) in a research note published on Tuesday, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.

Several other research firms have also commented on MOR. Berenberg Bank set a €150.00 ($174.42) price objective on shares of MorphoSys and gave the stock a buy rating in a research note on Monday, August 5th. JPMorgan Chase & Co. set a €120.00 ($139.53) price objective on shares of MorphoSys and gave the stock a buy rating in a research note on Wednesday, August 7th. Royal Bank of Canada set a €130.00 ($151.16) price objective on shares of MorphoSys and gave the stock a buy rating in a research note on Friday, August 9th. Deutsche Bank set a €133.00 ($154.65) price objective on shares of MorphoSys and gave the stock a buy rating in a research note on Thursday, August 8th. Finally, Goldman Sachs Group set a €114.00 ($132.56) price objective on shares of MorphoSys and gave the stock a neutral rating in a research note on Wednesday, August 7th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of €123.25 ($143.31).

ETR MOR opened at €107.00 ($124.42) on Tuesday. The company has a quick ratio of 7.40, a current ratio of 7.62 and a debt-to-equity ratio of 8.61. The firm has a market cap of $3.38 billion and a PE ratio of -81.00. The company has a 50 day moving average price of €99.27 and a 200 day moving average price of €91.79. MorphoSys has a 52 week low of €76.45 ($88.90) and a 52 week high of €114.60 ($133.26).

About MorphoSys

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.

Read More: Do equity income investments outperform growth and income investments?

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.